Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07744802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 7 entries
  2. Study completion moved earlier from Dec 2027 to Dec 2026
    • Primary completion date: Nov 2026 to Dec 2026
    • Start date: Aug 2026 to Sep 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
Trial Details
NCT Number NCT07744802
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions
(from sponsor)		 Healthy Male Participants
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov